Klavs F. Jensen Purchases 14326 Shares of SQZ Biotechnologies (NYSE:SQZ) Stock - Defense World - Financial Daily News Site

Klavs F. Jensen Purchases 14326 Shares of SQZ Biotechnologies (NYSE:SQZ) Stock – Defense World


SQZ Biotechnologies (NYSE:SQZ – Get Rating) Director Klavs F. Jensen purchased 14,326 shares of the business’s stock in a transaction on Wednesday, May 25th. The shares were acquired at an average price of $3.52 per share, with a total value of $50,427.52. Following the completion of the transaction, the director now owns 353,309 shares of the company’s stock, valued at $1,243,647.68. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

NYSE SQZ traded up $0.09 during trading on Friday, hitting $3.54. 135,080 shares of the company’s stock traded hands, compared to its average volume of 333,645. The stock has a fifty day moving average of $3.97 and a two-hundred day moving average of $7.08. SQZ Biotechnologies has a 12-month low of $2.73 and a 12-month high of $16.17. The firm has a market cap of $99.64 million, a P/E ratio of -1.31 and a beta of 3.73.

SQZ Biotechnologies (NYSE:SQZ – Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.06). SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%. On average, sell-side analysts anticipate that SQZ Biotechnologies will post -2.81 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. Citigroup Inc. boosted its holdings in shares of SQZ Biotechnologies by 139.6% during the third quarter. Citigroup Inc. now owns 2,595 shares of the company’s stock worth $37,000 after purchasing an additional 1,512 shares during the period. Royal Bank of Canada boosted its holdings in shares of SQZ Biotechnologies by 96.2% during the third quarter. Royal Bank of Canada now owns 3,059 shares of the company’s stock worth $44,000 after purchasing an additional 1,500 shares during the period. Bangor Savings Bank purchased a new stake in shares of SQZ Biotechnologies during the fourth quarter worth about $99,000. UBS Group AG lifted its holdings in SQZ Biotechnologies by 85.8% in the third quarter. UBS Group AG now owns 7,000 shares of the company’s stock worth $101,000 after buying an additional 3,233 shares during the period. Finally, Metropolitan Life Insurance Co NY purchased a new stake in SQZ Biotechnologies in the third quarter worth about $104,000. Institutional investors own 66.56% of the company’s stock.

Separately, Chardan Capital initiated coverage on shares of SQZ Biotechnologies in a research report on Wednesday. They set a “buy” rating and a $17.00 price target for the company.

SQZ Biotechnologies Company Profile (Get Rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

Further Reading



Receive News & Ratings for SQZ Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SQZ Biotechnologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Tags: #Klavs #Jensen #Purchases #Shares #SQZ #Biotechnologies #NYSESQZ #Stock #Defense #World

Leave a Comment